[1] Franco E,Bagnato B,Marino MG,et al.Hepatitis B: epidemiology and prevention in developing countries. World J Hepatol, 2012, 4: 74-80.
[2] Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med J (Engl), 2009, 122: 3-4.
[3] Maruyama T,Schodel F,Iino S,et al.Distinguishing between acute and symptomatic chronic hepatitis B virus infection. Gastroenterology, 1994, 106: 1006-1015.
[4] Chu CM,Yeh CT, Sheen IS,et al.Subcellular localization of hepatitis B core antigen in relation to hepatocyte regeneration in chronic hepatitis B. Gastroenterology, 1995, 109: 1926-1932.
[5] Hyodo N,Nakamura I, Imawari M.Hepatitis B core antigen stimulates interleukin-10 secretion by both T cells and monocytes from peripheral blood of patients with chronic hepatitis B virus infection. Clin Exp Immunol, 2004, 135: 462-466.
[6] Zlotnick A, Johnson JM, Wingfield PW,et al.A theoretical model successfully identifies features of hepatitis B virus capsid assembly. Biochemistry, 1999, 38: 14644-14652.
[7] Soeung SC, Rani M, Huong V, et al. Results from nationwide hepatitis B serosurvey in Cambodia using simple and rapid laboratory test: implications for National Immunization Program. Am J Trop Med Hyg, 2009, 81: 252-257.
[8] Deng LJ, Xu Y, Huang J. Developing a double-antigen sandwich ELISA for effective detection of human hepatitis B core antibody. Comp Immunol Microbiol Infect Dis, 2008, 31: 515-526.
[9] Han Y,Wang B and Liu H. The novel use of a routine quantitative system to analyze the activity, content and affinity of an antibody to hepatitis B core antigen. J Clin Virol, 2011, 52: 295-299.
[10] Liu H, Han Y, Wang B. A simple method to measure antibody affinity against the hepatitis B surface antigen using a routine quantitative system. J Virol Methods, 2011, 173: 271-274.
[11] Hadziyannis E, Manesis E, Vassilopoulos D, et al. Performance characteristics of microparticle enzyme and chemiluminescence immunoassays for measurement of anti-HBc immunoglobulin M in sera of patients with HBeAg-negative chronic hepatitis B virus infection. Clin Vaccine Immunol, 2008, 15: 385-387.
[12] EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 2012, 57: 167-185.
[13] Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology, 2010, 52: 454-461.
[14] Moucari R,Mackiewicz V,Lada O,et al.Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology, 2009, 49: 1151-1157.
[15] Tseng TC, Liu CJ, Su TH, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology, 2011, 141: 517-525, 525 e1-2.
[16] Tseng TC, Liu CJ, Yang HC, et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology, 2012, 55: 68-76.
[17] Liaw YF, Chu CM. Hepatitis B virus infection. Lancet, 2009, 373: 582-592.
[18] Song LW, Liu PG, Liu CJ, et al. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. Clin Microbiol Infect, 2015, 21: 197-203.
[19] Jia W,Song LW,Fang YQ,et al.Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study. Medicine (Baltimore), 2014, 93: e322.
[20] Zgair AK,Ghafil JA, Al-Sayidi RH. Direct role of antibody-secreting B cells in the severity of chronic hepatitis B. J Med Virol, 2015, 87: 407-416.
[21] Hou FQ,Song LW,Yuan Q,et al.Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon. Theranostics, 2015, 5: 218-226.
[22] Yuen MF,Yuan HJ,Hui CK,et al.A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut, 2003, 52: 416-419.
[23] Yuan Q, Song LW, Liu CJ, et al. Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. Gut, 2013. 62:182-184.
[24] Fan R,Sun J,Yuan Q,et al.Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut, 2016, 65: 313-320.
[25] Aurpibul L,Lumbiganon p,Kolasaraksa p,et al.HIV and Hepatitis B coinfection among perinatally HIV-infected Thai adolescents. Pediatr Infect Dis J, 2012, 31: 943-947.
[26] Karaosmanoglu HK,Aydin OA and Nazlican O.Isolated anti-HBc among HIV-infected patients in Istanbul, Turkey. HIV Clin Trials, 2013, 14: 17-20.
[27] Liu Y,Zeng P,Wang J,et al.Hepatitis B virus infection in a cohort of HIV infected blood donors and AIDS patients in Sichuan, China. J Transl Med, 2014, 12: 164.
[28] Urbani S,Fagnoni F, Missale G,et al.The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med, 2010, 48: 23-29.
[29] Raimondo G,Allain JP,Brunetto MR,et al.Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol, 2008, 49: 652-657.
[30] Li A,Yuan Q,Huang Z,et al.Novel double-antigen sandwich immunoassay for human hepatitis B core antibody. Clin Vaccine Immunol, 2010, 17: 464-469.
[31] Witt MD.Lewis RJ,Rieg G,et al.Predictors of the isolated hepatitis B core antibody pattern in HIV-infected and -uninfected men in the multicenter AIDS cohort study. Clin Infect Dis, 2013, 56: 606-612.
[32] Pallawela SN,Sonnex C,Mabayoje D,et al.Positive hepatitis B virus core antibody in HIV infection--false positive or evidence of previous infection J Med Virol, 2015, 87: 208-212. |
